Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Breast Cancer, Breast Tumors, Cancer of Breast
Interventions: Metformin, Atorvastatin, Breast surgery; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Burns
Interventions: Ketamine, Sodium chloride; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma
Interventions: JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more

Conditions: Pterygium
Interventions: CBT-001, Vehicle; Drug
Lead sponsor: Cloudbreak Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more

Conditions: Achondroplasia
Interventions: BMN 333, Vosoritide Injection [Voxzogo]; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Oakland, California • Wilmington, Delaware • Chicago, Illinois + 6 more

Conditions: Cerebrovascular Accident, Intracranial Hypertension
Interventions: 3-D ultrasound scanner, Perflutren Protein-Type A Microspheres for injection; Device · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Insomnia
Interventions: Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo), Placebo; Behavioral · Device · Drug + 1 more
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Arthritis, Juvenile Rheumatoid
Interventions: Celecoxib, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 31
States / cities: San Diego, California • Hartford, Connecticut • Delray Beach, Florida + 21 more

Conditions: Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions: Best Practice, Low Dose Radiation Therapy; Other · Radiation
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions: Polypill, Usual Care (individual medications prescribed by primary cardiologist); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Adverse Pregnancy Outcome
Interventions: Lovenox 40mg; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Seborrheic Keratosis
Interventions: A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Snellville, Georgia • Clinton Township, Michigan • Portland, Oregon + 2 more

Conditions: Covid19
Interventions: theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor; Drug
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 3,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2); Biological · Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypotension
Interventions: Nitroprusside; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bioequivalence
Interventions: Tacrolimus; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Discogenic Low Back Pain
Interventions: Platelet-Rich Plasma (PRP) Injection, Nucleus Pulposus (NP) Injection; Biological
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions: ENS-002; Biological
Lead sponsor: Concerto Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Hollywood, Florida • Beverly, Massachusetts • Austin, Texas

Conditions: Common Cold
Interventions: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more

Conditions: Patent Ductus Arteriosus
Interventions: feeding, fasting; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 23 Weeks to 33 Weeks
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 14
States / cities: San Francisco, California • San Jose, California • Chicago, Illinois + 11 more

Conditions: Delayed Graft Function
Interventions: Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA); Drug
Lead sponsor: Matthew Cooper; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

3-D Transcranial Ultrasound Analysis Study

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

Polypill in Acute Coronary Syndrome

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

PRP Versus NP Injections for Chronic Discogenic Low Back Pain

Topical ENS-002 for Atopic Dermatitis in Adults

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

Safety and Efficacy of a Drug Delivery System in Glaucoma

Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys